Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20647776 | 0.93 | MAPT (0.43) | MAPTTP53SMN1; SMN2CYP3A4CYP2D6 | |
| SCHEMBL19841949 | 0.91 | MAPT (0.43) | MAPTTP53SMN1; SMN2CYP3A4CYP2D6 | |
| SCHEMBL20647806 | 0.88 | MAPT (0.45) | MAPTTP53SMN1; SMN2HTTTSHR | |
| SCHEMBL19841961 | 0.88 | MAPT (0.34) | MAPTTP53SMN1; SMN2CYP3A4CYP2D6 | |
| SCHEMBL20647810 | 0.82 | CYP3A4 (0.41) | MAPTTP53SMN1; SMN2CYP3A4CYP2D6 | |
| SCHEMBL22818589 | 0.82 | CYP3A4 (0.53) | MAPTTP53SMN1; SMN2CYP3A4CYP2D6 | |
| SCHEMBL19841967 | 0.81 | CYP3A4 (0.36) | MAPTTP53SMN1; SMN2CYP3A4CYP2D6 | |
| SCHEMBL20647809 | 0.81 | CYP3A4 (0.41) | MAPTTP53CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16903194 | 0.80 | MAPT (0.58) | MAPTTP53SMN1; SMN2CYP3A4CYP2D6 | |
| SCHEMBL18387930 | 0.80 | MAPT (0.58) | MAPTTP53SMN1; SMN2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392349-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190016682-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016682-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | MAPT 4757/4885TP53 1049/4885SMN1; SMN2 4568/4885 |
| US-10392349-B2 | Azepane derivatives and methods of treating hepatitis B infections | HAVCR2, HDGF, AZI2 | MAPT 4757/4885TP53 1049/4885SMN1; SMN2 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.